Marijuana-based Drugs: Innovative Therapeutics or Designer Drugs of Abuse?
Table 1
Strategies to Circumvent Adverse Effects of CB1R Ligands
| Strategy | Representative Compound | Observed Effect(s) | Reference |
|---|---|---|---|
| Peripherally Restricted CB1R Ligands | URB-447 (CB1 antagonist) | ↓ Body Wt | (72) |
| SAB-378 (CB1 agonist) | ↓ GI Motility | (73) | |
| CB1R Allosteric Modulators | ORG-27569 (Negative AM) | ↑ Affinity | (74) |
| ↓ Function | |||
| PSNCBAM-1 (Negative AM) | ↓ Body Wt | (77) | |
| ↓ Excitability | |||
| FAAH Inhibitor | URB-597 | ↑ AEA | (83) |
| MGLL Inhibitor | JZL-184 | ↑ 2AG | (84) |
| CB1R Neutral Antagonist | AM-4113 | ↓ Body Wt | (89) |
| ↓ Adverse Effects | |||
